---
title: "Influx Healthtech Ltd (INFLUX) — Share Price, Financials & Analysis"
symbol: "INFLUX"
company: "Influx Healthtech Ltd"
canonical: "https://tapetide.com/stocks/INFLUX"
isin: "INE0MYZ01012"
nse_symbol: "INFLUX"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 629.92
generated_at: "2026-09-13T19:38:37.419Z"
---

# Influx Healthtech Ltd (INFLUX)

Canonical page: https://tapetide.com/stocks/INFLUX

## Company

- **NSE Symbol:** INFLUX
- **ISIN:** INE0MYZ01012
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-06-25
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** influxhealthtech.com

## About

Incorporated in 2020, Influx Healthtech Ltd is a CDMO which deals in nutraceuticals, Ready-to-Drink (RTD) beverages, functional nutrition and pet care.[1]

## Latest Price

- **Price:** ₹270.95
- **Change:** -3.85 (-1.4%)
- **Open:** ₹275
- **Day High:** ₹275
- **Day Low:** ₹270
- **Previous Close:** ₹274.8
- **Volume:** 8400
- **As Of:** 2026-09-11T09:58:39+00:00

## Key Fundamentals

Observed at 2026-09-11T04:51:54.655580Z.

- **Market Cap:** ₹629.92 Cr
- **Classification:** SME
- **P/E (reported):** 31
- **Book Value:** ₹43.52
- **Price to Book:** 6.31
- **Dividend Yield:** 0%
- **ROE:** 36.98%
- **ROCE:** 49.15%
- **Debt to Equity:** 0
- **Revenue (yearly):** ₹146.83 Cr
- **Net Income:** ₹20.11 Cr
- **EBITDA:** ₹29.86 Cr
- **52-Week High:** ₹315
- **52-Week Low:** ₹160.6
- **RSI (14):** 38.35

## Tapetide Score

- **Score:** 68 / 100
- **Score date:** 2026-09-04
- **Archetype:** Priced for Perfection
- **What it means:** The business scores well but the multiple leaves little room for error. The debate here is about the price, not the company; small disappointments tend to cost more at rich valuations.
- **Pillar profile:** Quality: Good · Valuation: Expensive · Momentum: Rising
- **Percentile:** 98.8 (of 4473 scored stocks)
- **Confidence:** 88%
- **Data coverage:** 76%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 87.13 | 9% |
| growth | 97.72 | 9% |
| momentum | 63.18 | 12% |
| ownership | 75.13 | 24% |
| quality | 74.82 | 22% |
| valuation | 34.14 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 39.1%

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 48.1 days to 83.5 days

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | -21.03% | 3.52% | 7.06% |
| ebitda margin growth | 2.18% | 18.53% | 91.18% |
| net income growth | 50.07% | 42% | 346.89% |
| revenue growth | 39.84% | 25% | 19.92% |
| roce | -25.01% | -40.16% | 59.06% |
| roe | -24.3% | 49.2% | -274.02% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Sales | 48 | 57 | 67 | 80 |
| Expenses | 39 | 45 | 52 | 65 |
| Operating Profit | 9 | 11 | 15 | 15 |
| OPM % | 19 | 20 | 22 | 19 |
| Other Income | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 2 | 2 | 2 |
| Profit before tax | 8 | 10 | 13 | 14 |
| Tax % | 27 | 24 | 23 | 25 |
| Net Profit | 6 | 8 | 10 | 11 |
| EPS in Rs | 3.1 | 4.21 | 4.32 | 4.56 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 0 | 59 | 76 | 100 | 105 | 147 |
| Expenses | 0 | 53 | 65 | 83 | 84 | 117 |
| Operating Profit | 0 | 6 | 11 | 17 | 21 | 30 |
| OPM % | — | 11 | 14 | 17 | 20 | 20 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 2 | 3 | 4 |
| Profit before tax | 0 | 6 | 10 | 15 | 18 | 27 |
| Tax % | — | 26 | 26 | 25 | 25 | 25 |
| Net Profit | 0 | 4 | 7 | 11 | 13 | 21 |
| EPS in Rs | 0 | 1800 | 2880 | 4452 | 7.37 | 8.87 |
| Dividend Payout % | — | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.03 | 0.03 | 0.03 | 0.03 | 18 | 23 |
| Reserves | 0 | 4 | 12 | 23 | 18 | 78 |
| Borrowings | 0 | 1 | 1 | 0 | 0 | 0 |
| Other Liabilities | 0 | 12 | 16 | 18 | 34 | 23 |
| Total Liabilities | 0 | 18 | 28 | 41 | 70 | 124 |
| Fixed Assets | 0 | 3 | 6 | 14 | 19 | 28 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 2 |
| Other Assets | 0 | 15 | 22 | 27 | 52 | 90 |
| Total Assets | 0 | 18 | 28 | 41 | 70 | 124 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0 | 4 | 7 | 9 | 7 | 4 |
| Cash from Investing Activity | 0 | -3 | -5 | -8 | -9 | -25 |
| Cash from Financing Activity | 0 | 1 | 0 | -1 | 0 | 45 |
| Net Cash Flow | 0 | 1 | 2 | 0 | -2 | 23 |
| Free Cash Flow | 0 | 1 | 2 | 1 | -1 | -21 |
| CFO/OP | — | 89 | 87 | 70 | 56 | 41 |

### Ratios

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | — | 64 | 66 | 58 | 113 | 84 |
| Inventory Days | — | 14 | 18 | 41 | 112 | 67 |
| Days Payable | — | 88 | 123 | 106 | 248 | 80 |
| Cash Conversion Cycle | — | -10 | -39 | -6 | -24 | 71 |
| Working Capital Days | — | 2 | 1 | 15 | 46 | 83 |
| ROCE % | — | 237 | 111 | 85 | 60 | 40 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2024 | Jun 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Promoters | 99.86% | 73.53% | 73.53% | 73.53% |
| FIIs | 0% | 3.38% | 1.83% | 0.16% |
| DIIs | 0% | 0.32% | 0.07% | 5.65% |
| Government | 0% | 0% | 0% | 0% |
| Public | 0% | 10.89% | 13.92% | 16.14% |
| Others | 0.14% | 11.87% | 10.65% | 4.52% |
| No. of Shareholders | 9 | 9 | 1022 | 1335 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 5 / 4 / 10

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 284.72 | Sell |
| EMA (10) | 283.14 | Sell |
| SMA (20) | 291.19 | Sell |
| EMA (20) | 287.34 | Sell |
| SMA (50) | 291.89 | Sell |
| EMA (50) | 285.45 | Sell |
| SMA (100) | 275.63 | Sell |
| EMA (100) | 273.27 | Sell |
| SMA (200) | 247.91 | Buy |
| EMA (200) | 248.68 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 36.13 | Neutral |
| MACD (12,26,9) | -3.57 | Sell |
| Stochastic (14,3,3) | 5.63 | Buy |
| ADX (14) | 20.46 | Neutral |
| Williams %R (14) | -97.5 | Buy |
| ATR (14) | 9.88 | High Volatility |
| ROC (12) | -10.4 | Sell |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 38.06 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 7 April 2026 - Newspaper ads published April 7, 2026 for corrigendum to April 6 postal ballot notice. | [Copy of Newspaper Publication 7 April 2026 - Newspaper ads published April 7, 2026 for corrigendum to April 6 postal ballot notice.](https://nsearchives.nseindia.com/corporate/INFLUX_07042026172232_070426IHLNewspaperAnnouncementSigned.pdf) |
| 6 April 2026 - Postal ballot corrigendum dated April 6, 2026 appoints Mr. Nayan P. Pitroda as scrutinizer. | [Corrigendum 6 April 2026 - Postal ballot corrigendum dated April 6, 2026 appoints Mr. Nayan P. Pitroda as scrutinizer.](https://nsearchives.nseindia.com/corporate/INFLUX_06042026174143_060426IHLIntimationofCorrigendumtoPostalBallotNoticeSigned.pdf) |
| 5 March 2026 - TBS confirmed GMP compliance for Influx's Palghar plant; inspection Dec 9, 2025; valid five years; enables Tanzania registration. | [Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals 5 March 2026 - TBS confirmed GMP compliance for Influx's Palghar plant; inspection Dec 9, 2025; valid five years; enables Tanzania registration.](https://nsearchives.nseindia.com/corporate/INFLUX_05032026183842_050326IHLGMPCertificatesigned.pdf) |
| 5 March 2026 - Influx Healthtech plant visit scheduled March 10, 2026 at Kolgaon, Palghar facility for investors/analysts. | [Analysts/Institutional Investor Meet/Con. Call Updates 5 March 2026 - Influx Healthtech plant visit scheduled March 10, 2026 at Kolgaon, Palghar facility for investors/analysts.](https://nsearchives.nseindia.com/corporate/INFLUX_05032026162633_050326IHLPlantVisitSEAnnouncementSigned.pdf) |
| 5 Jun - Promoter group held 1,70,23,464 shares as of March 31, 2026, with no new encumbrance. | [Disclosure under SEBI Takeover Regulations 5 Jun - Promoter group held 1,70,23,464 shares as of March 31, 2026, with no new encumbrance.](https://nsearchives.nseindia.com/corporate/team_sandeshc_22052026122018_41.pdf) |
| 4 February 2026 - Influx incorporated 100%-owned Olahey Wellness Pvt Ltd on Feb 3, 2026; paid-up capital Rs.100,000. | [Incorporation 4 February 2026 - Influx incorporated 100%-owned Olahey Wellness Pvt Ltd on Feb 3, 2026; paid-up capital Rs.100,000.](https://nsearchives.nseindia.com/corporate/INFLUX_04022026171421_InfluxHealthtechSusidiaryIncorporationSigned.pdf) |
| 31 March 2026 - Mar 31, 2026: Board approved altering IPO objects; postal ballot set; new independent director, secretarial auditor, committee reconstitutions. | [Appointment 31 March 2026 - Mar 31, 2026: Board approved altering IPO objects; postal ballot set; new independent director, secretarial auditor, committee reconstitutions.](https://nsearchives.nseindia.com/corporate/INFLUX_31032026163802_310326IHLBMOutcomeSigned.pdf) |
| 31 March 2026 - Board approved altering IPO objects (subject to shareholder postal ballot); appointed CS auditor and independent director on March 31, 2026. | [Appointment 31 March 2026 - Board approved altering IPO objects (subject to shareholder postal ballot); appointed CS auditor and independent director on March 31, 2026.](https://nsearchives.nseindia.com/corporate/INFLUX_31032026164027_310326IHLBMOutcomeSigned.pdf) |
| 31 March 2026 - Board approved altering IPO objects (postal ballot; cut-off March 27, 2026); appointed Independent Director Mohmad Saleh Mutvalli. | [Outcome of Board Meeting 31 March 2026 - Board approved altering IPO objects (postal ballot; cut-off March 27, 2026); appointed Independent Director Mohmad Saleh Mutvalli.](https://nsearchives.nseindia.com/corporate/INFLUX_31032026163146_310326IHLBMOutcomeSigned.pdf) |
| 30 April 2026 - Influx Healthtech states it is not a Large Corporate; outstanding borrowing was NIL on 31 March 2026. | [Updates 30 April 2026 - Influx Healthtech states it is not a Large Corporate; outstanding borrowing was NIL on 31 March 2026.](https://nsearchives.nseindia.com/corporate/INFLUX_30042026105448_30042026IHLInitialDisclosureSigned.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_30657_INFLUX_2025_2026_A_61168964_26082026155103.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_27446_INFLUX_2024_2025_A_14082025183648.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://nsearchives.nseindia.com/corporate/INFLUX_18112025161632_181125IHLEarningscallTranscriptsSigned.pdf) |
| Aug 2025 | [Concall - Aug 2025](https://nsearchives.nseindia.com/corporate/INFLUX_22082025161428_InfluxHealthtechAugust2025InvestorPresentation.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:38:37.419Z.